Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
spinal muscular atrophy
Biotech
Biohaven fails phase 3 SMA test but plans talks with FDA
The biotech plans to talk to the FDA about the next steps in SMA and is stepping up its interest in obesity on the strength of the data.
Nick Paul Taylor
Nov 25, 2024 9:56am
Phase 3 Scholar Rock trial hits SMA goal, sending stock up 327%
Oct 7, 2024 8:45am
Roche, Abu Dhabi partner to study rare spinal disease
May 23, 2024 5:30am
Novartis, Voyager launch $100M gene therapy mission
Jan 2, 2024 8:31am
David Liu's lab finds base editing may spur one-time SMA therapy
Mar 31, 2023 2:46pm
Celgene, Acceleron alum Backstrom tapped to lead Scholar Rock
Sep 20, 2022 11:20am
